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Abstract: Tobacco smoking during pregnancy remains common, especially in indigenous 
communities, and likely contributes to respiratory illness in exposed offspring. It is now 
well established that components of tobacco smoke, notably nicotine, can affect multiple 
organs in the fetus and newborn, potentially with life-long consequences. Recent studies 
have shown that nicotine can permanently affect the developing lung such that its final 
structure  and  function  are  adversely  affected;  these  changes  can  increase  the  risk  of 
respiratory illness and accelerate the decline in lung function with age. In this review we 
discuss  the  impact  of  maternal  smoking  on  the  lungs  and  consider  the  evidence  that 
smoking can have life-long, programming consequences for exposed offspring. Exposure 
to maternal tobacco smoking and nicotine intake during pregnancy and lactation changes 
the genetic program that controls the development and aging of the lungs of the offspring. 
Changes in the conducting airways and alveoli reduce lung function in exposed offspring, 
rendering  the  lungs  more  susceptible  to  obstructive  lung  disease  and  accelerating  lung 
aging.  Although  it  is  generally  accepted  that  prevention  of  maternal  smoking  during 
pregnancy and lactation is essential, current knowledge of the effects of nicotine on lung 
development does not support the use of nicotine replacement therapy in this group. 
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1. Introduction 
Recent  epidemiological  studies  have  shown  that  lung  function  and  susceptibility  to  respiratory 
diseases throughout life can be programmed by environmental factors operating during fetal and early 
postnatal life. One of the most common factors that can result in reduced lung function and respiratory 
health is exposure to maternal tobacco smoking, both before and after birth. Other factors include poor 
nutrition (both maternal and neonatal), maternal alcohol consumption, intra-uterine infections, early 
postnatal infections and exposure to allergens. For all of these, the timing of exposure in relation to 
lung development, as well as the level of exposure, will determine the severity of the effects on later 
lung function and respiratory illness. In this review we will focus on the immediate and long-term  
(or programming) effects of maternal tobacco smoking on lung development and respiratory function. 
As nicotine is a major component of tobacco smoke and has been identified as a risk factor for diseases 
in infants and children [1,2] we will emphasize the programming effects of early exposure to nicotine. 
In addition to effects on the lungs, nicotine exposure via the mother may affect the development of 
multiple organs; for example it has been shown to have long-lasting effects on body adiposity and 
endocrine function of offspring [3]. 
Although  smoking  during  pregnancy  is  the  leading  cause  of  fetal  morbidity  and  mortality  and 
obstetric disease, many pregnant women continue to smoke. In North America 20–25% of pregnant 
women smoke tobacco and in Spain this figure varies between 30% and 36% [4]. Although nearly 41% 
of  smokers  try to  quit  the  habit  each  year,  relapse  is  common,  and  only  about  10%  achieve  and 
maintain abstinence. The unpleasant effects of nicotine withdrawal account in part for the low success 
rate. Approved pharmacotherapies to treat nicotine dependence, such as nicotine replacement therapy 
(NRT) and Buproprion [5], have moderate efficacy. Thus additional and more effective therapies are 
required [6]. Varenicline appears to be one such therapy [7], provided that the benefits outweigh the 
risks to the mother and offspring. 
2. Effects of Maternal Tobacco Smoking on Lung Function and Respiratory Health of Offspring 
Prenatal and early postnatal exposure to tobacco smoke has a wide range of adverse health effects, 
including an increased risk of low birthweight and perinatal complications, the Sudden Infant Death 
Syndrome (SIDS), obstructive lung disease, altered neurodevelopment and childhood infections and 
cancers [8]. Arguably the most common of these is the adverse effect on lung function and respiratory 
health of perinatally exposed infants and children, and even adults. Clinical and epidemiological data 
from people whose mothers smoked tobacco have collectively provided strong evidence that exposure 
to the components of tobacco smoke during gestation and/or infancy can alter lung development such 
that later lung function and respiratory health are impaired. In infants prenatally exposed to maternal 
smoking, tidal and forced expiratory flow rates are reduced, suggesting that small airway development 
has been affected [9,10]. This is supported by studies in guinea pigs which showed that maternal Int. J. Environ. Res. Public Health 2011, 8                 
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smoke  exposure  during  pregnancy  affected  structural  and  functional  development  of  the  small 
conducting airways of the offspring soon after birth [11]. It is likely that changes in airway structure 
and  function  that  are  present  in  infancy  persist  until  childhood  and  potentially  into  adulthood. 
Numerous studies over the last 20 years have shown that children who are exposed to tobacco smoke 
during gestation are at increased risk of having airway hyperresponsiveness and asthma [12]. Prenatal 
smoke exposure in particular has been associated with reduced lung function in children, implicating 
restricted airflow in small conducting airways [13]. The effects of early smoke exposure on airway 
hyperresponsiveness appear to continue until at least early adulthood, suggesting that effects of smoke 
exposure on the small airways are permanent [14]. A potential mechanism for reduced lung function is 
a reduction in the number of alveolar-bronchiolar attachment points, due to reduced alveolarization.  
It is possible that maternal smoking could affect lung development by increasing oxidative stress in the 
lungs. However, the hypothesis that polymorphisms in maternal anti-oxidant genes could play a role in 
the adverse influence of maternal smoking on lung function in children was not supported by a recent 
study [15]. 
There is some evidence that lung function in adults could be affected by perinatal smoke exposure, 
independent of personal lifestyle [8,16]. Maternal smoking may also increase the risk of low FEV1 and 
COPD in adults [17], but it is presently unclear whether such effects are due to prenatal smoking or 
exposure to environmental tobacco smoke during infancy and childhood. 
3. Nicotine Uptake 
Nicotine is arguably the major physiologically active component of tobacco smoke and is rapidly 
absorbed from the respiratory tract of smokers. Although it has often been assumed that pulmonary 
absorption of nicotine from inhaled cigarette smoke is more rapid than by other routes (e.g., oral and 
transcutaneous), the lung appears to serve as a reservoir for nicotine, which slows its entry into the 
arterial circulation [18]. This implies that rather than all of the nicotine inhaled in each puff being 
absorbed in a few seconds, it may require 30–60 seconds or longer for the nicotine to be absorbed. 
Once  in  the  maternal  circulation,  nicotine  readily  crosses  the  placenta  and  enters  the  fetal  
circulation [19]; it can enter the amniotic fluid and from there it can be absorbed via the skin of  
the  fetus  [20].  Nicotine  enters  breast  milk,  and  can  reach  concentrations  that  are  approximately  
2–3  times  that  in  maternal  plasma.  This  is  primarily  due  to  the  partitioning  of  nicotine  into  the  
high-lipid-containing [21], more acidic milk [22,23]. 
The  typical  American  smoker  who  consumes  17  cigarettes  per  day  absorbs  systemically  about  
0.3 mg nicotine/kg body weight per day [24]. Blood or plasma nicotine concentrations sampled in the 
afternoon in cigarette smokers generally range from 10 to 50 ng/mL [25]. The tissues with the highest 
affinity for nicotine are the liver, kidney, spleen and lungs; the lowest affinity for nicotine is in adipose 
tissue. It also binds with high affinity to brain tissue [25,26]. 
When a pregnant woman smokes tobacco, nicotine enters the fetal circulation via the placenta. 
Although  nicotine  readily  crosses  the  placenta  there  is  no  evidence  that  it  is  metabolized  by  the 
placenta. It is therefore likely that the blood concentrations of nicotine reached in the fetus are similar 
to those in the mother; however, there is no direct evidence supporting the notion. Peak nicotine levels 
in the pregnant mother’s blood occur 15–30 minutes after it is administered [27]. Most of the nicotine Int. J. Environ. Res. Public Health 2011, 8                 
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that  enters  the  fetus  returns  to  the  maternal  circulation  for  elimination,  although  some  enters  the 
amniotic fluid via the fetal urine. Consequently nicotine and cotinine accumulate in the amniotic fluid 
of the pregnant smoker because the nicotine eliminated by the fetus is added to the nicotine coming 
from  the  blood  vessels  of  the  amniochorionic  membrane  [23].  The  fetus  is  therefore  likely  to  be 
exposed to nicotine even after concentrations in maternal blood have decreased. 
4. Metabolism of Nicotine during Pregnancy 
The clearance of nicotine and cotinine, the major product of nicotine metabolism, is increased in 
pregnant  women  [28].  This  can  be  ascribed  to  an  increase  in  liver  blood  flow  and  an  increased 
enzymatic  breakdown  of  nicotine  and  cotinine  in  the  mother.  Since  the  enzymatic  protection 
mechanisms of the fetus are not well developed [29-31], the metabolism of nicotine in the fetal liver is 
slow and a longer half-life of nicotine in the fetus can be expected. This is confirmed by the higher 
concentrations of nicotine in fetal tissue compared to maternal blood levels [32]. Consequently the 
cells of the developing lung and other organs are exposed to higher concentrations of nicotine for 
longer periods of time and thus to the adverse effects of nicotine on cell integrity. This is important as 
nicotine is genotoxic [33] and induces the release of oxidants [34]. Since rapidly dividing cells are 
more  vulnerable  to  the  effects  of  foreign  substances  such  as  nicotine  [35],  it  is  conceivable  that 
nicotine exposure during gestation and early postnatal life via maternal milk may interfere with growth 
and development. This can be achieved in two ways: by having a direct effect on cells and/or by 
reducing  the  nutrient  supply  to  the  fetus  during  gestation  and  lactation.  It  has  been  shown  that  
long-term nicotine exposure results in a predisposition for genetic instability [21,36,37]. This may 
result  in  changes  in  the  genetic  “program”  that  controls  lung  development,  maintenance  of  lung 
structure and aging of lung tissue, which may render the lungs more prone to disease. 
5. Nicotine and Oxidant/Antioxidant Status 
It has been shown that maternal smoking is associated with increased levels of oxidative stress 
markers in the mother and offspring [38,39]. There is also convincing in vivo and in vitro evidence 
suggesting  that  exposure  to  nicotine  results  in  oxidative  stress  in  fetal,  neonatal  and  adult  
tissues [39,40]. Reactive oxygen species (ROS) target mitochondria, and mitochondrial DNA has been 
shown to be more sensitive to the deleterious effects of ROS than nuclear DNA [41]. In addition, the 
electron transport chain enzyme complexes in the inner membrane of the mitochondria are extremely 
sensitive to ROS inactivation [42]. 
In addition to inducing overproduction of oxidants, nicotine exposure results in a decrease in the 
activity  of  SOD  and  catalase.  It  also  results  in  a  decrease  in  the  levels  of  low  molecular  weight 
antioxidants such as vitamins C and E [43]. Along with the decrease in the antioxidant capacity of the 
body,  concentrations  of  malondialdehyde  (MDA)  are  increased,  indicating  oxidant  damage  to  the  
cells [1,2]. The increase in ROS levels, together with a decrease in the activities of enzymes with 
antioxidant function, results in an imbalance in the oxidant/antioxidant capacity. This imbalance is 
maintained long after nicotine withdrawal [2] and becomes worse with age [34]. 
It is conceivable that the increased levels of nicotine-induced ROS in the fetus and suckling neonate 
as a consequence of maternal smoking or NRT will result in not only mitochondrial DNA damage but Int. J. Environ. Res. Public Health 2011, 8                 
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also damage of nuclear DNA. It is therefore likely that nicotine and ROS will result in a change in the 
capacity of the mitochondria to deliver energy and to participate in homeostatic mechanisms and in 
changing the “program” that controls growth, tissue maintenance, aging and cellular metabolism. 
6. Effects of Maternal Nicotine on Nutritional, Hormonal and Biochemical Profiles in  
the Offspring 
A number of studies indicate that some women who quit smoking during gestation relapse again 
during lactation. Lactation is a sensitive period during which cognitive and neurologic developments 
occur in suckling offspring. In a recent study it was shown that maternal nicotine intake, only during 
the period of lactation, leads to long-term effects on body weight (BW) regulation, leptin concentration, 
and  thyroid function  in adult  rat offspring  [44]. In  rat  experiments  it has  been  shown that,  when 
neonates  were  exposed  to  nicotine  in  milk  during  suckling,  their  circulating  catecholamine 
concentrations were higher than those of controls. After weaning, catecholamine levels decreased to 
normal but it is possible that the transient early adrenal medullary dysfunction caused by nicotine 
exposure may have a later impact on cardiovascular control in adult progeny [3]. 
7. Nicotine-Induced Body Malformations 
It is believed that the early period of organogenesis is the most vulnerable stage of embryogenesis 
to environmental insults [32]. Changing the in utero environment during early organogenesis may 
impair the process and in this way alter the structure and function of organs in the long term. Tobacco 
smoke introduces more than 4,000 chemicals into the circulation. Many of these chemicals, including 
nicotine, cross the placental barrier and enter the blood of the developing embryo and fetus. They can 
also enter the amniotic fluid and in this way alter the environment within which the embryo and fetus 
grows and develops. Nicotine is a major teratogenic component of tobacco smoke which can perturb 
embryogenesis.  Studies  in  rats  have  shown  that  nicotine  can  induce  embryonic  abnormalities,  
such  as  neural  tube  malformations,  before  and  during  the  early  stages  of  organogenesis,  in  a  
concentration-dependent manner [45]. The nicotine-induced embryonic malformations were associated 
with increases in programmed cell death in embryos. Nicotine can also cause cell death by increasing 
intracellular calcium levels and oxidative stress in the embryo [45]. Severe embryonic malformation 
may result in embryonic demise and is associated with higher spontaneous abortion and miscarriage in 
humans [46]. These malformations are thought to be caused by the nicotine-induced overproduction of 
ROS [45]. 
Animal studies show that a variety of antioxidants are effective in decreasing the damaging effects 
of heightened oxidative stress induced by teratogens. Effective antioxidants which might also be of 
clinical  value  include  vitamins  C  and  E,  carotenoids,  folic  acid,  as  well  as  synthetic  products. 
Appropriate clinical studies with antioxidants in pregnancies at high risk of developing oxidative stress 
are needed, since non-toxic antioxidants might prove an efficient and inexpensive way to reduce the 
rate of some serious and potentially fatal congenital anomalies [47]. 
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8. Effect of Nicotine on the Development of the Lung 
There is growing evidence that nicotine which is transported across the placenta may be the key 
constituent of cigarette smoke that alters lung development in offspring, thereby leading to impaired 
lung function and an increased risk of respiratory illness. After entering the fetal circulation, nicotine 
interacts with nicotinic acetylcholine receptors (nAChRs) in the fetal lung. This causes changes in lung 
structure and function in the offspring. Consistent with this, it has been shown that α3, α5, and α7 
nicotinic acetylcholine receptors (nAChR) are expressed in non-neuronal cells in the lungs of fetal 
monkeys, and that maternal nicotine exposure up-regulates nAChR expression in fetal lung [48]. High 
affinity nAChRs are found in the membranes of normal lung cells and in lung cancer cells of all 
histological types [49-51]. These include α3, α5, α7, and β2 or β4 subunits [50], of which α7 may help 
to modulate cell shape and affect cell-to-cell contact. It has been demonstrated that nicotine promotes 
cell proliferation upon its interaction with nAChRs on the surface of rodent bronchial epithelium and 
may contribute to dysanaptic lung growth [52].  
Fetal  exposure  to  nicotine  has  been  shown  to  reduce  the  surface  complexity  of  the  lung  
parenchyma,  increase  collagen  accumulation,  up-regulate  surfactant  protein  gene  expression,  and 
induce  neuro-endocrine  cell  hyperplasia  in  fetal  lungs;  collectively  these  changes  alter  pulmonary 
function [53]. In addition it has been shown that non-neuronal cells in lung synthesize acetylcholine 
(ACh), and that a cholinergic autocrine loop exists in developing lung [54]. Thus, prenatal nicotine 
exposure likely affects lung development by modifying the actions of this autocrine cholinergic loop. 
Much remains, however, to be determined about the mechanism by which nicotinic signaling alters 
lung development. 
Nicotine also activates several cellular pro-survival signals [55,56]. An example is the increase in 
the activity of protein kinase C (PKC) in various human and murine lung cancer cell lines when 
exposed to nicotine. Nicotine also elicits the activity of Raf-1 [57]. The activation of these kinases has 
been  shown  to  be  responsible  for the  phosphorylation  of Bcl-2  which  antagonizes  opioid-induced 
apoptotic signaling in lung cancer cells [49,58,59]. An increase in the phosphorylation of Akt has been 
detected in vivo in the lungs of nicotine-treated mice and in human lung cancer cells derived from 
smokers. The activation of this kinase is associated with tobacco-related carcinogenesis in the lung. 
The activation of these kinases in cultured cells that were transiently exposed to nicotine, suggests that 
nicotine directly or indirectly contributes to the process of lung carcinogenesis [49,55,59,60]. 
It has also been shown that long-term nicotine exposure results in a predisposition for the induction 
of genetic instability [36,37,61]. Gene amplification is a hallmark of gene instability. Gene instability 
requires  two critical elements,  namely an  inappropriate  cell  cycle progression, and DNA  damage. 
Long-term nicotine exposure, through the activation of Ras pathways and up regulation of cyclin D1, 
disrupts the G1 arrest. It also augments the production of ROS which may lead to DNA damage. This 
implies that exposure to nicotine via tobacco smoke or via NRT will make the lungs more prone to the 
development of cancer [36]. Int. J. Environ. Res. Public Health 2011, 8                 
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9. Effects of Nicotine on Metabolic Activity in the Lung 
9.1. Energy Metabolism 
Glucose uptake and metabolism are essential for the proliferation and survival of cells, and may be 
enhanced in actively proliferating cell systems such as embryonic tissue. Glucose is considered to be 
an essential source of energy in lung tissue [62] and is necessary for the functional development of the 
lung  [63-65].  Glucose  is  also  the  main  source  of  α-glycerophosphate  for  pulmonary  surfactant 
synthesis in the adult lung while in fetal lung, the loss of cellular glycogen from alveolar type II cells 
just before birth is associated with increased surfactant synthesis [66]. During the alveolar phase of 
lung development, which occurs from around week 36 of gestation in humans [67], lung tissue is more 
dependent on glycogen as an energy substrate than adult lung. This is illustrated by the fact that during 
fasting  the  phosphorylase  activity  of  adult  lung  tissue  decreases  to  conserve  glycogen  while  it 
increases in fetal and neonatal lung, thereby increasing the utilization of the lung glycogen stores. This 
means that  the control of glycogen  metabolism  during the alveolar  phase of lung  development is 
different from that of adults [68]. 
Although glucose and glycogen are the primary energy substrates of adult and developing lung, 
fatty acids are also important. For example, during fasting, when blood fatty acid levels are elevated, 
fatty  acids replace glucose as  the primary energy substrate.  Under  these circumstances glucose is 
conserved  by  the  lung  for  α-glycerophosphate  synthesis  and  eventual  surfactant  formation  by  the  
type II alveolar epithelial cells [69]. 
Nicotine exposure during gestation and the early postnatal period results in sustained suppression of 
glycogenolysis and glycolysis in lung tissue (Figure 1) [70,71]. The lower glycogenolytic activity is 
due to a lower phosphorylase activity in the lungs of nicotine exposed offspring [71]. The ratio of 
inactive to active phosphorylase of lung tissue of nicotine exposed offspring is the same as for animals 
that were not exposed to nicotine via the placenta and mother’s milk. However, the tissue levels of 
both phosphorylase fractions are lower than in the lungs of the control animals, which implies that the 
total phosphorylase content of the lungs of the nicotine exposed animals was lower than that of the 
control animals. This means that maternal nicotine exposure suppresses the synthesis of phosphorylase 
in the lungs of the offspring. It also implies that maternal nicotine exposure had no direct inhibitory 
effect on the activity of the phosphorylase in the lungs of the offspring. The lower rate of glycogen 
breakdown in the lungs of animals that were exposed to nicotine via the placenta and mother’s milk 
was due to a permanent lower glycogenolytic activity. The implication is that the developing fetal and 
neonatal  lungs  of  these  animals  are  more  dependent  on  exogenous  glucose  for  utilization  via  the 
hexose monophosphate shunt than on glucose derived from the lung’s glycogen stores [71]. 
The  uptake  of  exogenous  glucose  is  carried  out  by  glucose  transporters.  Glucose  transporter 
isoforms 1 (Glut 1) and 4 (Glut 4) are not present in adult lung, but are present in developing lung [72]. 
Over-expression of these Glut isoforms can enhance glucose uptake into fetal lungs to support active 
cell proliferation, which is a common characteristic of developing lung epithelium [73]. The decrease 
in the flux of glucose through the glycolytic pathway of lungs of nicotine exposed rat pups is, however, 
not due to compromised glucose transporters because the total glucose turnover of the lung tissue of 
rats that were exposed to nicotine via the placenta and mother’s milk is higher than in animals that Int. J. Environ. Res. Public Health 2011, 8                 
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were not exposed to nicotine. The higher glucose flux is actually due to a faster utilization of glucose 
via the hexose monophosphate shunt [74]. After nicotine withdrawal the flux of glucose through the 
glycolytic pathway remained suppressed to the same degree than while exposed to nicotine (Figure 1). 
After nicotine withdrawal, the flux of glucose through the hexose monophosphate pathway returns to 
normal [70]. In addition to the reduced flux of glucose through the glycolytic pathway [70], AMP 
accumulates in the lungs of the nicotine exposed rat pups [75]. 
Figure 1. The influence of maternal nicotine exposure during gestation and lactation on: 
(A)  glucose  (Control  vs.  Experimental  groups:  P  <  0.001),  (B)  glycogen  utilization 
(Control  vs.  Experimental  groups:  P  <  0.001)  and  (C)  lactate  production  (Control  vs. 
Experimental groups: P < 0.01) by lung tissue of the offspring.  
 
Hatched bars show data from Control offspring (postnatal days 21 and 42 data combined); Grey 
bars show data from Nicotine exposed offspring killed at postnatal day 21; Black bars show data 
from a Withdrawal group at postnatal day 42. In the Withdrawal group, nicotine was not available 
from weaning on postnatal age 21 until the animals were killed at day 42; a period of 21 days of 
nicotine  withdrawal  was  allowed  to  establish  the  longer  term  effect  of  nicotine  exposure  on 
carbohydrate metabolism by lung tissue of the offspring. Age-matched Control tissue was used in 
each case [68,71]. Data are presented as mean ±  SEM. 
Both the persistent reduction in glycolytic activity and high levels of AMP are associated with 
premature onset of cell senescence [76,77]. This is supported by studies showing that enhancement of 
glycolysis prevents cellular senescence [78]. It is, therefore, conceivable that nicotine exposure during 
gestation and suckling induces premature aging of the lungs by irreversible suppression of glycolysis 
and the persistent high levels of AMP in the lungs of the offspring (Figure 2). Int. J. Environ. Res. Public Health 2011, 8                 
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Figure  2.  Diagram  to  illustrate  the  factors  that  induce  premature  aging  of  the  lung 
parenchyma of rats exposed to nicotine via tobacco smoke or nicotine replacement therapy 
(NRT) via the placenta and mother’s milk. Premature aging of the lung is associated with 
an increased propensity for emphysema. 
 
9.2. Xenobiotic Metabolism 
The respiratory system is one of the major targets for exposure to exogenous substances [79]. A 
major source of exogenous chemicals to which the respiratory system is exposed is inhaled tobacco 
smoke [80]. In addition to exposure to air-borne substances the respiratory system is also exposed to 
chemicals  via  the  systemic  circulation  [81].  This  is  particularly  true  during  gestation  when  the 
developing lungs are exposed to chemicals transferred to the fetus from the maternal circulation, and 
during lactation when compounds are conveyed to the newborn via the mother’s milk [82]. As nicotine 
freely  crosses  the  placenta  [83]  and  occurs  in  significant  quantities  in  the  milk  of  smoking  
mothers [82], it can interact with the developing fetus and neonate of mothers who either actively 
smoke tobacco or use NRT. 
It is widely accepted that the cytochrome P450 (CYP) superfamily of enzymes is the principal 
means by which the lung metabolizes exogenous substances [79]. Upon entering the lung many of the 
chemicals are not hazardous as such, but are frequently biotransformed by CYP enzymes into reactive 
intermediates. A critical factor contributing to the etiology or modification of respiratory disease is 
whether the  lung  tissue  has  the  ability  to  activate  or  efficiently  inactivate  chemicals  [83].  Recent 
studies have indeed shown that maternal nicotine exposure during gestation and lactation results in a 
permanently elevated expression of CYP2A3 and CYP 2B1 [84]. It has been shown that CYP2A6 
plays an important role in the formation of cancer-inducing agents such as 4-(methylnitrosoamino)- 
(3-pyridyl)-1-butanone  (NNK).  It  is  also  known  that  the  rat  orthologue  of  CYP2A3  induces  the 
synthesis of NNK [85]. The permanent increase in expression of these CYPs may thus increase the 
susceptibility of the lungs of nicotine exposed offspring to cancer.  
The  Mn-Zn  SOD  activity  of  the  developing  lungs  is  also  reduced  by  nicotine  exposure  which 
further reduces the ability of the lungs to be protected against the point mutations in DNA induced by 
oxidants;  this  will  increase  the  susceptibility  of  exposed  lungs  to  changes  in  the  “program”  that 
controls lung development, maintenance and aging.  
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10. Effects of Nicotine on Structural Development of the Lungs 
Fibroblasts play a critical role in the transition from the saccular to the alveolar stage of lung 
development, during which there is a four-fold increase in the number of interstitial fibroblasts in the 
neonatal rat lung [86]. Perturbations such as hyperoxia, barotrauma and steroid therapy have been 
shown to interfere with alveolar development in the rat [87], baboon [88] and human [89], the net 
result of which is a significant, often permanent, decrease in the number of alveoli. 
Although the control of alveolar formation is poorly understood, a substantial body of evidence 
exists regarding events that coincide with alveolar septation, many of which may influence fibroblast 
proliferation. Elastic fibers are thought to be involved in septation by providing structural support for 
newly emerging secondary septa. Inhibition of elastic fiber assembly has been linked to impaired 
septation and alveolarization [90]. In neonatal rat lung fibroblasts, elastin expression peaks during the 
second  postnatal  week,  that  is  during  the  phase  of  rapid  alveolarization,  and  declines  rapidly  
thereafter  [91].  This  means  that  interference  with  lung  fibroblast  integrity  may  result  in  impaired 
formation of alveoli, which may lead to a permanent reduction in the number of alveoli. 
Exposure to cigarette smoke inhibits fibroblast proliferation and migration by increasing cell cycle 
transit time, thereby reducing the rate of alveolarization [92]. Consequently the surface area available 
for gas exchange is reduced; another effect of reduced alveolarization is a reduction in the number of 
alveolar-bronchiolar attachments, which can lead to airway narrowing [93]. Cigarette smoke exposure 
also compromises fibroblast-induced repair responses, and may be one of the factors that contributes to 
the development of smoke-induced lung diseases [94]. Accumulation of nicotine in fibroblasts will 
affect glycolysis  and  plausibly  fibroblast  function  too.  However,  in  vitro  studies  have  shown that 
nicotine  has  no  effect  on  fibroblasts  from  human  fetal  lungs  [94].  In  vivo  studies  also  show  that 
nicotine only has a transient effect on metabolism in lungs of adult animals, as opposed to a permanent 
suppression  of  energy  metabolism  of  animals  that  were  exposed  to  nicotine  during  lung  
development  [75].  The  in  vitro  studies  on  fibroblasts  were  performed  on  cells  that  were  not 
metabolically permanently compromised as opposed to the fibroblasts of lung cells of neonatal rats 
that had been exposed to nicotine during gestation and lactation. Therefore, since nicotine exposure 
during  gestation  and  lactation  interferes  with  glucose  metabolism  and  apoptosis  in  the  fetal  and 
neonatal lung, and since it may cause disruption of the interaction between lung fibroblast glucose 
metabolism  and  fibroblast  function,  it  is  plausible  that  it  will  also  adversely  affect  the  long-term 
maintenance  of  lung  structure.  It  is  interesting  to  note  that  lung  fibroblasts  from  patients  with 
emphysema show a reduced proliferation rate [95] and premature aging [96] and that this condition is 
characterized by slow degeneration of the lung parenchyma [97]. Therefore, the gradual deterioration 
of  the  connective  tissue  framework  of  the  lungs  of  nicotine  exposed  rat  pups  (Figure  3)  may  be 
partially due to inadequate fibroblast proliferation and function. 
Many agents that induce lung injury may do so by modifying key metabolic events for various cell 
populations in the lung. Type I alveolar epithelial cells for example, which cover more than 90% of the 
alveolar surface [98], depend on glycolysis for energy [99]. Glycolysis also supplies the ATP required 
to maintain the membrane-linked Na + -K + ATPase [100]. The Na + -K + ATPase pump plays a vital 
role in maintaining cell volume. Therefore, reducing its activity by inhibition of glycolysis will result 
in the swelling of these cells and the formation of membrane “blebs” [101]. Int. J. Environ. Res. Public Health 2011, 8                 
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Figure 3. Effect of maternal nicotine exposure during pregnancy and lactation in rats on 
the connective tissue framework (stained black) of the lung of adult offspring. Note that the 
connective tissue framework of the control lungs (A) is more extensive than that of the 
offspring that were exposed to nicotine via the mother (B) [102]. 
(A)  (B) 
   
 
Inhibition  of  glycolysis  would  therefore  be  expected  to  interfere  with  the  ability  of  the  type  I 
alveolar epithelial cells to adapt to changes in the environment and to maintain cell volume. Since 
pulmonary glycolysis is irreversibly suppressed in animals that were exposed to nicotine during lung 
development, the activity of the Na + -K + ATPase pump will also be permanently lower in type I 
epithelial  cells,  and  this  could  result  in  membrane  blebbing  and  rupture  of  the  cell  membranes  
(Figure 4). The type I epithelial cells are the most vulnerable to injury [102] and the permanently 
reduced glycolytic activity will therefore make them even  more susceptible to damage, especially 
when exposed to toxic substances in blood and inhaled air. 
Alveolar type II cell proliferation has been found to be increased in the lungs of nicotine exposed 
animals, which is a likely response to type I cell injury and death [103]. Type II alveolar epithelial 
cells  are  critical  for  the  maintenance  of  alveolar  homeostasis  by  secreting  surfactant  and  by 
proliferating and  differentiating to replace damaged type  I cells  [104];  in effect these cells act in 
defense  of  the  alveolus.  It  has  also  been  shown  that  maternal  nicotine  exposure  during  gestation  
and  lactation  induces  rapid  type  II  alveolar  epithelial  cell  proliferation  in  response  to  type  I  cell  
damage  [105-107].  Since  rapid  cell  proliferation  is  associated  with  rapid  shortening  of  the  
telomeres [108], it is conceivable that premature aging of the type II cells will occur in the lungs of the 
nicotine exposed rats. This may result in an increased vulnerability of the alveolus, which is supported 
by the observation that loss of type II cells has a detrimental effect on the alveolus [106].  Int. J. Environ. Res. Public Health 2011, 8                 
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Figure 4. Scanning electron micrographs of the alveolar surface in postnatal rats showing 
(A) control lung, (B) blebbing of the alveolar type I cell membrane in a nicotine exposed 
animal and (C) rupture of the alveolar surface to reveal the underlying capillary filled with 
red blood cells in a nicotine exposed animal. The nicotine exposed rats received nicotine 
during gestation and lactation. All animals were sacrificed on postnatal day 21 and lung 
tissue processed for scanning electron microscopy [102]. 
(A)  (B)  (C) 
     
It appears that the negative impact of maternal nicotine exposure during gestation and lactation on 
the growth, development and repair processes of the lungs of the offspring causes lung structure to 
more rapidly deteriorate with age than in animals that were not exposed to nicotine. This is illustrated 
by  the  appearance  of  membrane  blebs  (Figure  4),  alveolar  fenestrations  [109]  and  eventually 
microscopic emphysema (Figure 5). The elastic tissue framework (Figure 3) of the lungs of nicotine 
exposed animals is also compromised [110]. Exposure of fetal monkeys and rats to nicotine via the 
placenta during the late saccular/early alveolar phase of lung development results in an increase in the 
size  of  the  primitive  alveoli;  as  a  consequence  the  alveolar  surface  area  for  gas  exchange  in  the  
adult  lung  is  decreased  [109,111].  Collectively,  the  structural  changes  in  the  lungs  of  these  
animals resembles faster aging of the lungs, and are likely to make the lungs more susceptible to 
respiratory disease.  
The gradual deterioration of the lung parenchyma with increasing age is clearly due to an inability 
of the lung epithelium and fibroblasts to maintain the structural integrity of the lungs. This effect is 
likely due to premature aging of the fibroblasts [96] and alveolar epithelial cells [112], which can be 
attributed to altered “programming” due to the changes in the in utero environment [111,113,114]. 
The  reason  for  the  altered  “programming”  is  not  clear.  It  is  known  that  nicotine  induces 
peroxidation of membrane lipids. It also reduces the anti-oxidant capacity of the lungs [40,115]. Since 
oxidants [33] and nicotine [116] can induce point mutations in DNA (Figure 2), it is possible that the 
imbalance  in  the  oxidant/antioxidant  status  of  the  nicotine-exposed  developing  lung  results  in  the 
altered “programming” and consequently the lower glycolytic capacity of the lungs [70], as well as the 
drastic increase in AMP [75]. This theory is supported by the observation that maternal vitamin C 
supplementation during pregnancy and lactation prevents the lowering of the glycolytic capacity of the 
lungs  of  nicotine-exposed  offspring  [40]  as  well  as  the  development  of  microscopic  emphysema  
(G Maritz, unpublished data). It is therefore plausible that restoration of the oxidant/antioxidant status Int. J. Environ. Res. Public Health 2011, 8                 
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of the mother and offspring will prevent altered “programming” and thus premature aging of the lungs 
of the offspring. 
Figure 5. The effect of nicotine exposure via the mother during pregnancy and lactation on 
the parenchyma of the lung tissue of adult offspring. The alveoli of the control lungs (A) 
are smaller than those of the lungs that were exposed to nicotine (B).  
(A)  (B) 
 
 
It  has  been  demonstrated  that  in  utero  exposure  to  nicotine  increases  DNA  methylation  and 
acetylation in the fetus. Nicotine also alters gene methylation in cultured human esophageal squamous 
epithelial cells [117]. It is therefore plausible that some of the longer term effects of maternal nicotine 
exposure  on  the  respiratory  system  of  the  offspring  are  due  to  epigenetic  changes.  It  has  been 
suggested that the rapid induction of insulin resistance in rats exposed to nicotine during gestation and 
lactation is a reflection of an acute epigenetic response and not a genetic predisposition [118]. It is thus 
plausible that the effects of maternal nicotine exposure on the metabolism and lung structural integrity 
of the offspring are due to epigenetic changes rather than changes to the DNA. 
11. Nicotine and Cell Signaling: Apoptosis and Lung Development 
Programmed cell death or apoptosis is an energy-dependent and genetically controlled process [119] 
that  can  be  induced  by  a  number  of  molecular  tools  [120].  Apoptosis  occurs  in  the  pulmonary 
mesenchyme as early as day 14 of gestation in the rat, when branching of conducting airways is the 
predominant feature. The percentage of cells undergoing apoptosis increases dramatically between 18 
and 22 days of gestation and remains elevated in the first day of postnatal life. 
During  the  phase  of  rapid  alveolarisation  between  postnatal  days  4  and  13  in  rats,  which 
corresponds to week 36 of gestation in humans [67], interstitial fibroblasts undergo rapid proliferation. 
Few alveoli are formed after this phase. Between postnatal days 13 and 21 the number of fibroblasts 
and  type  II  cells  decreases.  This  decrease  in  fibroblasts  and  type  II  cells  occurs  by  means  of 
programmed  cell  death  or  apoptosis,  which  peaks  between  postnatal  days  17  and  19.  Apoptosis 
therefore  plays  a  key  role  in  the  thinning  of  the  alveolar  septa  that  occurs  after  the  cessation  of 
alveolarisation [121,122].  Int. J. Environ. Res. Public Health 2011, 8                 
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Cigarette  smoke  inhibits  the  proliferation  and  migration  of  human  lung  fibroblasts  and  
fibroblast-mediated responses and in this way can contribute to the development of emphysema [94]. 
Nicotine and its metabolite cotinine inhibit apoptosis in fibroblasts [123], but the mechanism is not 
known. Nicotine is known to exert its effects on many cell types via nicotinic cholinergic receptors.  
It  has  been  suggested  that  pediatric,  smoking-associated  pulmonary  diseases  and  small  cell  lung 
carcinoma  may  be  caused  by  the  direct  chronic  stimulation  of  an  α7-nicotinic  acetylcholine  
receptor-initiated  autocrine  loop  by  nicotine  and  NNK,  where  NNK  is  formed  from  nicotine  by 
nitrosation in the body and during curing of tobacco [124,125]. It is also possible that certain effects of 
nicotine are not receptor mediated and may operate through unconventional nicotine receptors [123]. 
There is evidence that nicotine: (a) activates the mitogen-activated protein kinase (MAP) signaling 
pathway and extracellular signal-regulated kinase (ERK-2), resulting in increased expression of the 
Bcl-2  protein  and  inhibition  of  apotosis,  and  (b)  blocks  the  inhibition  of  protein  kinase  C  (PKC) 
activity in lung cells. Nicotine appears to have no effect on the activities of c-jun NH-2-terminal 
protein kinase (JNK), c-myc or p28 MAP kinases that are involved in apoptosis. While exposure to 
nicotine can result in the activation of two major signaling pathways (MAP-kinase and PKC) that are 
known to inhibit apoptosis, nicotine regulation of MAP and ERK kinase activity is not dependent on 
PKC. These effects of nicotine occur at concentrations that are generally found in the blood of smokers, 
and could lead to disruption of the critical balance between cell death and proliferation [58,126]. The 
inhibition of apoptosis by nicotine may contribute to the slower thinning of the alveolar septa of the 
lungs of rat pups that were exposed to nicotine during gestation and suckling [127]. Experimental data 
suggests that nicotine exposure of the fetus and newborn during the phases of rapid cell division may 
render  the  lungs  more  susceptible  to  the  development  of  cancer  [53].  No  epidemiologic  data  are 
currently  available  to  support  this  suggestion, although  the  risk  of  other  forms  of  cancer  may  be 
increased by prenatal exposure to tobacco smoke [128,129].  
It has been suggested that in utero exposure of pulmonary neuro-endocrine cells to nicotine or NNK 
may contribute to the development of pediatric lung disorders such as bronchitis and lower respiratory 
illnesses [53] along with altered pulmonary mechanics in infants and children [130]. The alterations in 
lung function in monkeys prenatally exposed to nicotine parallel those observed in infants of mothers 
who  smoke  during  pregnancy  [130].  These  alterations  in  lung  function  could  be  induced  via  two 
mechanisms. The first is a direct effect of released 5-hydroxytryptamine (5-HT) in response to α7 
nicotinic receptor stimulation of bronchial and vascular smooth muscle and fibroblast growth; the 
second is an indirect effect of 5-HT on pulmonary neuro-endocrine cell numbers via activation of a 
Raf-1/MAP kinase pathway, resulting in yet more cells that can synthesize and release 5-HT. Chronic 
exposure to nicotine and NNK during early development may therefore up-regulate the α7 nicotinic 
receptor  as  well  as  components  of  its  associated  mitogenic  signal  transduction  pathway,  thereby 
increasing the vulnerability of infants to the development of pediatric lung disorders [48]. 
12. Nicotine and Immune Response. 
The development of immune systems begins during fetal life and proceeds into early neonatal life. 
This renders them very vulnerable to changes in the environment to which the fetus and neonate are 
exposed, and may have lasting effects on the immune function of the individual. It has been shown that Int. J. Environ. Res. Public Health 2011, 8                 
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in adults cigarette smoke is a risk factor for upper respiratory tract infections [131]. Some of the effects 
of cigarette smoke on the immune system, such as lowered serum IgG and decreased activity and 
numbers of natural killer cells, may be attributed to nicotine. It was indeed shown in rodents that 
adolescent nicotine treatment results in impaired T-cell immune responses well after nicotine exposure 
was terminated. It is therefore plausible that nicotine exposure during early development modulates 
allergic responses and thereby increases the susceptibility of the offspring to asthma in later life [132]. 
13. Nicotine Replacement Therapy (NRT) 
Recently it has been suggested that all pregnant women should stop smoking immediately because 
if a mother abstains from smoking during the first three months of her pregnancy, the risks to the fetus 
are the same as those of a fetus of a non-smoking mother [4]. Nicotine replacement therapy (NRT) is 
prescribed  by  many  health  professionals  to  assist  smokers  to  quit the  habit.  Various  products  are 
currently  available  to  provide  nicotine  in  order  to  reduce  the  craving  for  smoking;  these  include 
nicotine containing gums, patches, lozenges, and sprays [133] as well as electronic cigarettes. NRT has 
been recommended to assist women to quit smoking when they become pregnant. Although NRT is 
widely prescribed by health professionals as an aid to stop smoking, it is questionable whether nicotine 
intake during pregnancy and lactation is safe for the fetus and neonate. 
The use of NRT is widely promoted because it is often thought that nicotine is not harmful [4]. 
However, several studies show that nicotine can damage the fetal lungs, heart, and the central nervous 
system. Nicotine is genotoxic [4,33] and its toxic effects persist in the fetus after administration has 
stopped  [4].  Studies  in  non-human  primates  [104]  clearly  show  that  nicotine  exposure  during 
pregnancy increases the development of α7 nicotinic receptors in cells implicated in lung development. 
Pulmonary hypoplasia and other abnormalities in pulmonary and bronchial development have been 
found in the offspring after exposure to nicotine during gestation [48,70,108,111]. It is also evident 
that nicotine exposure during development suppresses lysyl oxidase activity and this could contribute 
to the gradual deterioration of the lung parenchyma of the offspring. Furthermore, nicotine induces 
peroxidation of membrane lipids [84] which changes the oxidant/anti-oxidant status of the lungs of the 
offspring.  This  is  supported  by  the  decrease  in  the  vitamin  C  and  E  content  of  the  lungs  of  the 
offspring [134]; these lungs also clearly show a decrease in the levels of the enzymes that catalyze the 
removal of antioxidants from the lung. Our studies show that the level of superoxide dismutase in the 
lungs of rats that were prenatally exposed to nicotine remains significantly lower than that of rats not 
exposed to nicotine (G Maritz, unpublished data). This implies that, apart from its immediate effect in 
the lungs of those who use NRT, maternal nicotine intake during pregnancy and lactation will have a 
long-term effect on the maintenance of lung integrity and respiratory health of exposed offspring [42]. 
14. Conclusions 
Maternal nicotine exposure during gestation and lactation, and therefore by implication maternal 
tobacco smoking (and perhaps tobacco chewing), results in a change in the program that controls the 
development and aging of the lungs of offspring. Changes in the conducting airways and alveoli render 
the  lungs  of  the  offspring  more  susceptible  to  disease  and  reduced  lung  function.  Although  it  is 
generally accepted that prevention of maternal smoking during pregnancy and lactation is essential, the Int. J. Environ. Res. Public Health 2011, 8                 
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considerable evidence of adverse effects on exposed offspring indicates that it is not appropriate to 
prescribe NRT to pregnant women. 
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